Resultantly, a magnificentdual EZH2/HSP90 inhibitor was pinpointed that exerted striking cellgrowth inhibitory efficacy against TMZ-resistant Glioblastoma (GBM)cell lines. This evidence concerns the gene EZH2 and glioblastoma.